Pharmafile Logo

#RemoteDetailing

- PMLiVE

Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

FDA rejects Waylivra, Roivant group continues gene therapy drive, UK biotech gains £637k

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

Roche Diagnostics’ chief heads for the exit

No surprise if Diggelmann resurfaces at diagnostics start-up or rival

- PMLiVE

It’s a no for Yescarta, says NICE on heels of EU approval

Gilead gets rapid knock-back from cost effectiveness watchdog

- PMLiVE

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

Drug increased PFS by 2.6 months compared to Pfizer’s Sutent

- PMLiVE

Shire claims US okay for HAE blockbuster-in-waiting

FDA approves Takhzyro as a preventative measure for HAE attacks

- PMLiVE

Vertex appoints new commercial lead amid NHS, Orkambi price war

Ludovic Fenaux will succeed Simon Bedson

- PMLiVE

UK says firms should stockpile drugs in case of no-deal Brexit

Government also confirms the MHRA will handle UK marketing applications for new medicines

Mastering the precision medicine opportunity

The rise of precision medicine will transform the pharma business model, challenging the way we commercialise therapies. BLH Senior Consultant and precision medicine expert David Cooney, reveals how you can...

Blue Latitude Health

EISAI

Eisai’s Lenvima wins European liver cancer indication

EC green-lights the RTK inhibitor as a first-line treatment

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

- PMLiVE

HSJ Partnership Awards will showcase pharma’s inspirational joint working projects with the NHS

Health Service Journal (HSJ), the news and information service for all healthcare leaders working in, for, or with the NHS, has expanded and enhanced its Partnership Awards for 2019.

Wilmington Healthcare

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links